Efficacy in terms of responses rate after maintenance therapy
| . | Premaintenance (%) . | VT (%), n = 91 . | VP (%), n = 87 . | P . |
|---|---|---|---|---|
| IF− CR, n (%) | 62 (24) | 42 (46) | 34 (39) | NS |
| IF+ CR, n (%) | 26 (10) | 9 (10) | 10 (11) | NS |
| PR, n (%) | 122 (47) | 36 (39) | 41 (47) | NS |
| MR, n (%) | 21 (8) | 3 (3) | 1 (1) | NS |
| SD, n (%) | 25 (10) | 1 (1) | 1 (1) | NS |
| . | Premaintenance (%) . | VT (%), n = 91 . | VP (%), n = 87 . | P . |
|---|---|---|---|---|
| IF− CR, n (%) | 62 (24) | 42 (46) | 34 (39) | NS |
| IF+ CR, n (%) | 26 (10) | 9 (10) | 10 (11) | NS |
| PR, n (%) | 122 (47) | 36 (39) | 41 (47) | NS |
| MR, n (%) | 21 (8) | 3 (3) | 1 (1) | NS |
| SD, n (%) | 25 (10) | 1 (1) | 1 (1) | NS |
Data are number with percentages (%).
VT indicates bortezomib plus thalidomide; VP, bortezomib plus prednisone; IF− CR, negative immunofixation complete response; IF+ CR, positive immunofixation complete response; PR, partial response; MR, minor response; SD, stable disease; and NS, not significant.